This paper attempts to demonstrate that the present governance challenges facing policy makers in the WTO and its member states with regard to the public health crises in developing countries cannot be simply overcome by modifying the TRIPs Agreement. One argument pursued in this paper is that any move towards an ex peditious solution must first of all acknowledge the significance of market con straints for the corporate pharmaceutical supply model; and, second, that public health governance policies formulated by governments in both developing and developed countries revolve around the ideological and political preference for market norms and values as operatives of distributive justice. Whilst it is true that TRIPs does constrain the autonomy of governments in developing countries to better manage their public health needs, the paper poses the question as to whether the time is right to rethink the concept of public health and essential medicines in the age of globalization.
Abbott, F.M. (1998), 'The Enduring Enigma of TRIPs: A Challenge for the World Economic System', Journal of International Economic Law, 1: 497.
2.
—. ( 2002a), WTO, TRIPs Agreement and its Implications for Access to Medicines in Developing Countries, London: Commission on Intellectual Property Rights.
3.
—. ( 2002b), 'Compulsory Licensing for Public Health Needs: The TRIPs Agenda at the WTO after The Doha Declaration on Public Health', Occasional Paper 9. Geneva: Quaker United Nations Office.
4.
Annan, K. (2001), 'Working Together', Business in Africa, February 2000.
5.
Baggott, R. (2000), Public Health: Policy and Politics. Basingstoke: Macmillan.
6.
Balance, Robert, James Pogany and Helmet Forsteiner (1992). 'The World's Pharmaceutical Industries: An International Perspective on Innovation, Competition and Policy'Vienna: UNDIO.
7.
Bala, K., O. Lanza and S.R. Kam. (1998), 'Retail Drug Prices: The Law of the Jungle', HAI News, April: 1.
8.
Balasubramaniam, K. (2002), 'Access to Medicines and Public Policy Safeguards under TRIPs', Conference on Multi-Stakeholder Dialogue on Trade, Intellectual Property and Biological Resources in Asia, Rajendrapur, Bangladesh: BRAAC Centre for Development Management, 19-21 April.
9.
Bala, K. and K. Sagoo. (2000), 'Patents and Prices'. HAI News, April-May: 1.
10.
Bale, H.E. (1997), 'Patent Protection and Pharmaceutical Innovation ', New York University Journal of International Law and Politics , 29(1/2).
11.
Boseley, S. (2002), 'There is a Danger that WHO's New Partnership with Drug Companies will Skew its Health Policies', The Guardian , 6 February.
12.
Brundtand, G. (2001), 'Bridging the Health Divide: The Way Forward' , address to the 54th WHA, 14 May. Available at http://www.who.int/director-general/speeches/2001/english/20010514_wha54.html .
13.
Bruno, K., and J. Karliner. (2000), 'Tangled up in Blue', CorpWatch, 1 September (available at http://www.corpwatch.org/campaigns/PCD.jsp?articleid=996).
14.
Corpwatch. (1998), 'Citizens Compact on the United Nations and Corporations', 28 January (available at http://www.corpwatch.org/campaigns/PCD.jspParticieid=992).
15.
Challu, P.M. (1991), 'The Consequences of Pharmaceutical Product Patenting ', World Competition, 15(2): 65-126.
16.
Commission On Intellectual Property Rights (Cipr). (2002), Integrating Intellectual Property Rights and Development Policy. London: CIPR.
17.
Correa, C. (1994) 'The GATT Agreement on Trade-Related Aspects of Intellectual Property Rights: New Standards for Patent Protection', European Intellectual Property Review, 16(8): 327.
18.
—. (1998), 'Implementing the TRIPs Agreement in the Patents Field: Options for Developing Countries', Joumal of World Intellectual Property, 1(1): 75-77.
19.
—. (2000b), Integrating Public Health Concerns into Patent Legislation in Developing Countries. Geneva: South Centre.
20.
—. (2000a). Intellectual Property Rights, the WTO and Developing Countries: The TRIPs Agreement and Policy Options. London : Third World Network.
21.
—. (2002), Protection of Data Submitted For the Registration of Pharmaceuticals: Implementing the Standards of the TRIPs Agreement. Geneva: South Centre.
22.
Drahos, P. (2002), 'Developing Countries and International Intellectual Property Standard-Setting', Commission on Intellectual Property Rights Background Paper 8London: CIPR.
23.
Fink, C. (2000), 'How Stronger Patent Protection in India Might Affect the Behaviour of Transnational Pharmaceutical Industries', Policy Research Paper Number 2352. Washington DC: World Bank.
24.
FORTUNE. (2002), 'Fortune 500 = Drug Industry Most Profitable Again', 3 April.
25.
Geitner, P. (2002), 'EU Proposal to Increase Access to Drugs for Poor Countries Attacked by Activists as "Impracticable"', AP Business Writer, 24 June. (available at http:/story.news.yahoo.com/news?tmpl=story&u=/ap/20020624/ap-wo_en_po/eu_wto_drug-patents_2).
26.
Hai. (2001), 'Public-Private Partnerships: Addressing Public Health Needs or Corporate Agendas?' Available at http://www.haiweb.org/campaign/PPI/seminar200011.doc .
27.
Hardin, G. (1968), 'The Tragedy of the Commons', Science, 162: 1243.
28.
Kettler, H., and H. Collins. (2002), 'Using Innovative Action to Meet Global Health Needs through Existing Intellectual Property Regimes', Commission on Intellectual Property Rights Background Paper 1a. London : CIPR (available at http://iprcommission.org).
29.
Kumar, N. (2002), 'Intellectual Property Rights, Technology and Economic Development: Experiences of Asian Countries', Commission on Intellectual Property Rights Background Paper 1bLondon: CIPR.
30.
Kokkonen, P.T., and M. Kehomaki. (1993), 'Legal and Economic Issues in European Public Health' in C.E.M. Normand and P Vaughan (eds), Eunope without Frontiers, pp. 35-39. London: John Wiley
31.
Keon, J. (2002), 'Fast Generic Relief for the Cost of Pharmaceuticals' , The Global and the Mail, 24 January.
32.
Lasker/Funding First. (2002), 'Investing in Research: The Unfinished Business Model of Business Research' . Available at http://www.foundation.org/reports/pdf/invest.pdf .
33.
Lanjouw, J. (1998), 'The Introduction of Pharmaceutical Product Patents in India: Heartless Exploitation of the Poor and Suffering?'. Working Paper 6366. Yale University, USA: NBER .
34.
Lanjouw, J., and Cockburn, I. (2000), 'Do Patents Matter? Empirical Evidence After GATT', NBER Working Paper 7495. Yale University, USA: NBER.
35.
London School Of Hygiene And Tropical Medicine. ( 2002), New Products into Old Systems: The Initial Impact of the Global Alliance for Vaccines and Immunization (GAVI) at Country Level . UK: Save the Children.
36.
Lohr, S. (2002) 'On Intellectual Property: US Forgets its Own Past ', International Herald Tribune, 16 October.
37.
Mansfield, E. (2000), 'Intellectual Property Protection, Direct Investment and Technology Transfer: Germany, Japan and the USA, International Journal of Technology Management, 19(1 and 2): 4-16.
38.
Maskus, K. (2000), Intellectual Property Rights in the Global Economy . Washington DC: IIE.
39.
Medecins Sans Frontiere (Msf). (2001), 'Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARV's for Developing Countries'. Geneva: MSF.
40.
Mirza, Z. (2002), 'Linking Drug Prices with Inflation will Amplify Miseries of the Poor'. Available at http://www.healthnet.org/programs/edrug.html .
41.
Nogues,J. (1990), 'Patents and Pharmaceutical Drugs: Understanding the Pressures on Developing Countries', Journal of World Trade , 24(6): 82-85.
42.
Oxfam. (2001a) Patent Injustice: How World Trade Rules Threaten the Health of the Poor. Oxfam (available at: http://www.oxfam.org.uk/cutthecost ).
43.
—. (2001b), 'Priced Out of Reach', Briefing Paper Number 4. UK: Oxfam.
44.
—. (2002), 'TRIPs and Public Health: The Next Battle', Briefing Paper Number 15: Oxfam (available at http://www.oxfam.org/eng/pdfs/pp020325_TRIPs_health.pdf).
45.
Pharmaceutical Research And Manufacturers Of America (Phrma). (2002), Health Care in the Developing World , Washington DC: PhRMA (available at http://www.world.phrma.org/healthcare.devel.world.html p2).
46.
Pacon, A.M. (1996), 'What Will TRIPs do for Developing Countries?' in Friedrich-Karl Beier and Gerhard Schricker (eds), From GATT to TRIPs: The Agreement on Trade-Related Aspects of Intellectual Property Rights. Munich: Max Planck Institute.
47.
Perry. G. (1998), 'Globalisation of Pharmaceuticals: Effects of Trade Agreements on Intellectual Property and Public Health', oral presentation . Geneva: WHO, 13 October (available at http://www.egagenerics.com/facts_figures/intellectual_property/who_presentation_98.htm ).
48.
Richter, J. (2002), 'Codes in Content: TNC Regulation in an Era of Dialogues and Partnerships', Cornerhouse Briefing Paper No. 26. UK: Cornerhouse (available at http://cornerhouse.icaap.org ).
49.
Stiglitz. J. (1999), 'Knowledge as a Global Public Good', in I. Kaul, I. Grunberg and M. Stern (eds), Global Public Goods in the 20th Century: International Cooperation in the 20th Century. Oxford: Oxford University Press.
50.
Smith A. (1976), Wealth of Nations. Oxford: Claundon Press (Glasgow edition 1776).
51.
Stiglitz, J. (2002), Globalisation and Its Discontents. US: Penguin.
52.
United States Trade Representative (Ustr). ( 2002), A second Communication from the United States of America Relating to paragraph 6 of the Doha Declaration on the TRIPs Agreement and Public Health'. Available at http://www.ustr.gov/releases/2002/06/02-56.htm .
53.
Watal, J. (2000), Pharmaceutical Patents, Prices and Welfare Losses: Policy Options for India Under the WTO TRIPs Agreement. Oxford: Blackwell Publishers.
54.
—. (2001a), 'Background Note to Workshop on Differential Pricing and Financing of Essential Drugs: WHO-WTO Secretariat Workshop of 8-11 April 2001. Geneva: WHO, pp. 4-7.
55.
—. (2001b), Intellectual Property Rightsin the WTO and Developing Countries. Boston: Kluwer.
56.
Weismann, Robert. (1996), 'A Long, Strange TRIPs: The Pharmaceutical Industry Drive to Harmonize Global Intellectual Property Rules and the Remaining WTO Legal Alternatives Available to Third World Countries', University of Pennsylvania Journal of Economic Law, 17: 1069.
57.
World Bank. (2001). Human Development Report 2001. Washington DC: World Bank.
58.
World Health Organization (2001), Macroeconomics and Health: Investing in Health for Economic Development, Geneva: WHO.
World Trade Organization (1991), Negotiating Group on TRIPs: Meeting of Negotiation Group of 27 and 28 June 1991 (MTN. CNG/TRIPs/1)Geneva: WTO.
61.
—. (1997), India: Patent Protection for Pharmaceutical and Agricultural Chemical Products (WT/DS50/R [Panel Report] and WT/DS50/AB/R [Appellate Body Report])Geneva: WTO.
62.
—. (2001), 'Declaration on the TRIPs Agreement and Public Health', WT/MIN(01)/DEC/2. Geneva: WTO.
63.
Weismann, R. (2001), "'Free Trade" and Medicines in the Americas', Foreign Policy in Focus, 6(13): 1-4 (available at http://www.fpif.org/bridfs/vo16/v6n13meds.html )
64.
Yamey, G. (2001), 'Global Vaccine Initiative Creates Inequity. Analysis Concludes', British Medical Journal, 322 (31 March): 754.
